Assistant Professor at the University of Vermont Cancer Center and today we'll be discussing the article “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An ...

During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...

BMS said that this is the first regimen showing a statistical benefit over PD-1 monotherapy such as Opdivo (nivolumab) in metastatic melanoma ... the combination of relatlimab and nivolumab ...

The US regulator cleared BMS' LAG-3 drug relatlimab ... Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with unresectable or metastatic melanoma.